

# Longitudinal Urban Cohort Ageing Study

<https://www.neurodegenerationresearch.eu/survey/longitudinal-urban-cohort-ageing-study-2/>

## **Title of cohort**

Longitudinal Urban Cohort Ageing Study

## **Acronym for cohort**

LUCAS

## **Name of Principal Investigator - Title**

Dr

## **Name of Principal Investigator - First name**

Ulrike

## **Name of Principal Investigator - Last name**

Dapp

## **Address of institution -Institution**

ertinen-Haus, Centre for Geriatrics and Gerontology, Research Department

## **Address of institution - Street address**

Sellhopsweg 18-22

## **Address of institution - City**

Hamburg

## **Address of institution - Postcode**

22459

## **Country**

Germany

## **Website**

[www.geriatrie-forschung.de](http://www.geriatrie-forschung.de)

## **Contact email**

[email protected]

**Funding source**

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Alzheimer's disease and other dementias| Neurodegenerative disease in general

**Q1b. When are studies on the above condition(s) expected to become possible?**

Already Possible

**Q2a. In a single sentence what is the stated aim of the cohort?**

To enlighten the black box of the ageing process by establishing a longitudinal cohort making use of a randomised controlled trial (RCT) carried out in 2000 with over 3,300 independent senior citizens in the community of Hamburg. Information about pre-clinical markers for healthy ageing vs. the development of functional decline, has been collected multidimensionally in an interdisciplinary process since 2000.

**Q2b. What distinguishes this cohort from other population cohorts?**

**Q3a. i) Number of publications that involve use of your cohort to date**

0

**Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)**

**Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**

**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population**

**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years  
From:**

60

**Q4a. Study criteria: what is the age range of participants at recruitment? To:**

98

**Q4b. Study criteria: what are the inclusion criteria?**

patients 60 + years in participating general practices (GP) in Hamburg in year 2000

**Q4c. Study criteria: what are the exclusion criteria?**

patients needing help in basic activities of daily life; patients obtaining nursing care according to the German long-term care insurance (Pflegeversicherung I-III); patients with cognitive impairment; patients with terminal disease and/or patients unable to understand German

**Q5. What is the size of the cohort (i.e. how many participants have enrolled)?**

1,000-5,000 participants

**Q6a. Please describe what measures are used to characterise participants**

multidimensional dataset using self-administered questionnaires in waves with whole cohort plus multidimensional assessments with randomly selected subgroups

**Q6b. Are there additional measures for participants with a clinical disorder?**

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

Yes

**If yes please specify**

functional status, nursing care (Pflegestufe), death

**Q7. What is the study design (select all that apply)?**

Longitudinal

**Q8. Are your cases matched by**

Age

**Q9a. Does your study include a specialised subset of control participants?**

Yes

**Q9b. If your study includes a specialised subset of control participants please describe**

**Q10a. i) Please enter the data collection start date**

01/12/2000

**Q10a. ii) Please enter the data collection end date**

**Q10a. iii) Is data collection for this study**

Data collection ongoing| Data analysis ongoing

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

Yes - intend to apply for funding

**Q11. Is data collected**

**Other please specify here**

**Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?**

**Q13a. Please give information on the format and availability of data stored in a database (1)**

% available

**Q13a. Please give information on the format and availability of data stored in a database (2)**

% available

**Q13a. Please give information on the format and availability of data stored in a database (3)**

% available

**Q13a. Please give information on the format and availability of data stored in a database (4)**

% available

**Other (please specify)**

% available

**Q13b. Please give information on the format and availability of data held as individual records (1)**

% available

**Q13b. Please give information on the format and availability of data held as individual records (2)**

% available

**Q13b. Please give information on the format and availability of data held as individual records (3)**

% available

**Q13b. Please give information on the format and availability of data held as individual records (4)**

% available

**Please specify language used**

**Q14a. Is data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Other criteria (only for LUCAS consortium partners until end of funding)

**Q15. What data sharing policy is specified as a condition of use?**

Data made publicly available after a specified time point

**Q16a. Are tissues/samples/DNA available to other groups?**

No

**Q16b i) If yes, please describe below:**

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

**Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

**Q17. Is information on biological characteristics available to other groups?**

No

**Number of Patients**

**% of total cohort**

**Types:**

Population Cohorts

**Member States:**

Germany

**Diseases:**

Alzheimer's disease & other dementias, Neurodegenerative disease in general

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A